急性HIV感染期间启动抗逆转录病毒治疗后可溶性CD163水平正常化与更少神经系统异常相关
研究在泰国急性HIV感染者中检测血浆和脑脊液可溶性CD163水平,并评估中枢神经系统受累。Fiebig III期患者cART前sCD163升高、cART后正常化,且cART后较高sCD163与不良CNS指标相关。作者认为急性HIV感染早期(Fiebig I/II期)启动cART可能减少炎症、防止CD163脱落,从而可能降低脑损伤风险。
要点
- Fiebig III期患者cART前血浆sCD163为135 ng/mL、脑脊液为10 ng/mL,均高于未感染对照(P均<.01)。
- Fiebig III期患者cART后血浆sCD163降至90.1 ng/mL、脑脊液降至6.5 ng/mL。
- cART后Fiebig III期较高sCD163水平与较差的神经心理测试评分等不良CNS指标相关。
核心结论
- 急性HIV感染早期(即Fiebig I/II期)启动cART可能减少炎症、防止CD163脱落,进而可能降低脑损伤风险。
研究设计与样本
- 在泰国急性HIV感染(Fiebig I-IV期)启动cART的成人中,用酶联免疫吸附试验检测血浆和脑脊液可溶性CD163水平,并以神经心理测试和磁共振波谱分析脑代谢物评估CNS受累。
- 慢性HIV感染或未感染的泰国人作为对照。
- 共检查51名急性HIV感染成人(Fiebig I-III期;男性>90%;年龄31岁)。
主要发现
- Fiebig I/II期cART前后sCD163水平与未感染对照相当:血浆分别为97.9和93.6 ng/mL vs 99.5 ng/mL,脑脊液分别为6.7和6.4 ng/mL vs 7.1 ng/mL。
- Fiebig III期cART前sCD163水平高于未感染对照(血浆135 ng/mL;脑脊液10 ng/mL;P均<.01),cART后正常化(血浆90.1 ng/mL;脑脊液6.5 ng/mL)。
- cART前,Fiebig III期较高sCD163水平与较差的CNS指标相关(如N-乙酰天冬氨酸水平降低),而Fiebig I/II期该关联反而与较好的CNS结局相关(如较高神经心理测试评分)。
- cART启动后,Fiebig III期较高sCD163水平与不良CNS指标相关(如较差的神经心理测试评分)。
临床怎么用
- 作者认为急性HIV感染早期(即Fiebig I/II期)启动cART可能减少炎症、防止CD163脱落,进而可能降低脑损伤风险。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Myeloid activation contributes to cognitive impairment in chronic human immunodeficiency virus (HIV) infection. We explored whether combination antiretroviral therapy (cART) initiation during acute HIV infection impacts CD163 shedding, a myeloid activation marker, and in turn, implications on the central nervous system (CNS). METHODS: We measured soluble CD163 (sCD163) levels in plasma and cerebrospinal fluid (CSF) by enzyme-linked immunosorbent assay in Thais who initiated cART during acute HIV infection (Fiebig stages I-IV). Examination of CNS involvement included neuropsychological testing and analysis of brain metabolites by magnetic resonance spectroscopy. Chronic HIV-infected or uninfected Thais served as controls. RESULTS: We examined 51 adults with acute HIV infection (Fiebig stages I-III; male sex, >90%; age, 31 years). sCD163 levels before and after cART in Fiebig stage I/II were comparable to those in uninfected controls (plasma levels, 97.9 and 93.6 ng/mL, respectively, vs 99.5 ng/mL; CSF levels, 6.7 and 6.4 ng/mL, respectively, vs 7.1 ng/mL). In Fiebig stage III, sCD163 levels were elevated before cART as compared to those in uninfected controls (plasma levels, 135 ng/mL; CSF levels, 10 ng/mL; P < .01 for both comparisons) before normalization after cART (plasma levels, 90.1 ng/mL; CSF levels, 6.5 ng/mL). Before cART, higher sCD163 levels during Fiebig stage III correlated with poor CNS measures (eg, decreased N-acetylaspartate levels), but paradoxically, during Fiebig stage I/II, this association was linked with favorable CNS outcomes (eg, higher neuropsychological test scores). After cART initiation, higher sCD163 levels during Fiebig stage III were associated with negative CNS indices (eg, worse neuropsychological test scores). CONCLUSION: Initiation of cART early during acute HIV infection (ie, during Fiebig stage I/II) may decrease inflammation, preventing shedding of CD163, which in turn might lower the risk of brain injury.
引用
- D'Antoni ML, Byron MM, Chan P, et al. Normalization of Soluble CD163 Levels After Institution of Antiretroviral Therapy During Acute HIV Infection Tracks with Fewer Neurological Abnormalities. J Infect Dis. 2018. PMID: 29868826. doi:10.1093/infdis/jiy337
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。